Literature DB >> 27741010

Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?

Helen M Heneghan1, Claire Donohoe, Jessie Elliot, Zuhair Ahmed, Vinod Malik, Narayamasamy Ravi, John V Reynolds.   

Abstract

OBJECTIVE: The aim of this study is to assess CT-PET and endoscopic assessment postneoadjuvant chemoradiotherapy (nCRT) in predicting complete pathologic response (pCR) in locally advanced esophageal cancer (LAEC).
DESIGN: A prospective cohort study.
BACKGROUND: nCRT is increasingly standard of care in LAEC, with pCR a surrogate for excellent outcome. Predicting pCR before surgery, with metabolic imaging and endoscopy, may spare patients' operative intervention.
METHODS: One hundred thirty-eight consecutive patients [mean age 61 ± 8, 99 male (72%), 103 (75%) adenocarcinoma] underwent nCRT with CT-PET and endoscopy 4 to 6 weeks later, and surgery subsequently. A complete metabolic response (cMR) was defined as SUVmax of <4. A complete endoscopic response (cER) was no residual mucosal abnormality. The association of pCR with cMR and cER was analyzed.
RESULTS: pCR was achieved in 30 patients (22%); 37% SCC and 17% adenocarcinoma. A cMR was evident in 63 (46%), of whom 17 (27%) had a pCR and 17(27%) were ypN+. A cER was observed in 45 (33%). The Spearman correlation for cER and cMR was 0.066 (P = 0.479), for cER and pCR was 0.004 (P = 0.969), and cMR and pCR -0.120 (P = 0.160). The sensitivity, specificity, positive predictive value, and negative predictive value of cMR was 57%, 57%, 27%, and 82%, respectively, and for combined cMR and cER was 24%, 83%, 28%, and 79%, respectively.
CONCLUSIONS: The prediction of pCR through CT-PET and endoscopy independently or combined is limited by low sensitivity and poor positive predictive value. Protocols to avoid surgery in patients with apparent complete clinical complete based on these criteria should be adopted with considerable caution.

Entities:  

Mesh:

Year:  2016        PMID: 27741010     DOI: 10.1097/SLA.0000000000001902

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

1.  Cancer of the esophagus and esophagogastric junction: an 8th edition staging primer.

Authors:  Claire L Donohoe; Alexander W Phillips
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.

Authors:  Amorn Tamtai; Chuleeporn Jiarpinitnun; Pitichote Hiranyatheb; Nattawut Unwanatham; Eakapop Sirachainun; Chairat Supsamutchai; Poompis Pattaranutaporn; Nuttapong Ngamphaiboon
Journal:  Med Oncol       Date:  2017-08-07       Impact factor: 3.064

Review 3.  Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials.

Authors:  Claire L Donohoe; John V Reynolds
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

4.  18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.

Authors:  Mian Xi; Zhongxing Liao; Wayne L Hofstetter; Ritsuko Komaki; Linus Ho; Steven H Lin
Journal:  J Nucl Med       Date:  2017-05-18       Impact factor: 10.057

Review 5.  Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma.

Authors:  Kazuto Harada; Dilsa Mizrak Kaya; Anthony Lopez; Hideo Baba; Jaffer A Ajani
Journal:  Ann Transl Med       Date:  2018-02

6.  PET Imaging and Rate of Pathologic Complete Response in Esophageal Squamous Cell Carcinoma.

Authors:  M Hart Squires; Nicole Gower; Jennifer H Benbow; Erin E Donahue; Casey E Bohl; Roshan S Prabhu; Joshua S Hill; Jonathan C Salo
Journal:  Ann Surg Oncol       Date:  2021-10-09       Impact factor: 5.344

7.  Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.

Authors:  Kazuto Harada; Xuemei Wang; Yusuke Shimodaira; Tara Sagebiel; Manoop S Bhutani; Jeffrey H Lee; Brian Weston; Elena Elimova; Quan Lin; Fatemeh G Amlashi; Dilsa Mizrak Kaya; Anthony Lopez; Mariela A Blum Murphy; Jack A Roth; Stephen G Swisher; Heath D Skinner; Wayne L Hofstetter; Jane E Rogers; Irene Thomas; Dipen M Maru; Ritsuko Komaki; Garrett Walsh; Jaffer A Ajani
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

8.  Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer.

Authors:  Sophie E Vollenbrock; Jolanda M van Dieren; Francine E M Voncken; Sietze T van Turenhout; Liudmila L Kodach; Koen J Hartemink; Johanna W van Sandick; Berthe M P Aleman; Regina G H Beets-Tan; Annemarieke Bartels-Rutten
Journal:  Eur Radiol       Date:  2020-01-21       Impact factor: 5.315

9.  Clinical predictors of pathologically response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: long term outcomes of a phase II study.

Authors:  Zihui Tan; Hong Yang; Jing Wen; Kongjia Luo; Qianwen Liu; Yihuai Hu; Lanjun Zhang; Mengzhong Liu; Jingping Yun; Jianhua Fu
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

10.  Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma.

Authors:  Zhigang Wu; Qiang Zheng; Haiquan Chen; Jiaqing Xiang; Hong Hu; Hang Li; Yunjian Pan; Yizhou Peng; Xingxin Yao; Pengcheng Liu; Yihua Sun; Bin Li; Yawei Zhang
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.